Back
ESC Premium Access

Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline

Session: Poster Session 2 - Cardiovascular risk and its modification
Topic: Antidiabetic Pharmacotherapy
Speaker: Doctor D. Fitchett (Toronto, CA)
Event: ESC Congress 2018

Congress Presentation

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)
18 presentations
0 follower

5 more presentations in this session

Sex-specific analysis on efficacy and safety of statins: a systematic review and quantitative meta-analysis

Speaker: Miss M. Schreuder (Rotterdam, NL)

Access
Abstract
Slides
Thumbnail

Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention

Speaker: Professor P. Meikle (Melbourne, AU)

Access
Abstract
Slides
Thumbnail

Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)

Access
Abstract
Thumbnail

LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS

Speaker: Professor G. De Ferrari (Turin, IT)

Access
Abstract
Slides
Thumbnail

Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5

Speaker: Professor S. Bain (Swansea, GB)

Access
Abstract
Slides
Thumbnail

Access the full session

Poster Session 2 - Cardiovascular risk and its modification

Speakers: Doctor D. Fitchett, Miss M. Schreuder, Professor P. Meikle, Professor S. Verma, Professor G. De Ferrari...
Access
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb